Though CDK4/6 inhibition is a promising approach for the treatment of bladder cancer, however, mechanisms of resistance are unclear. Therefore, a genome-scale CRISPR-dCas9 GOF screen for the CDK4/6 inhibitor was performed. 1024 sgRNAs were significantly enriched in the screen. Combination of Palbociclib with compounds directed against RTKs, PI3K-Akt, Ras/MAPK and STAT pathways revealed beneficial effects in vitro and in vivo xenografts. In conclusion, identification of resistance mechanisms and rational combinational therapies could be achieved by CRISPR-dCas9 approach.
«
Though CDK4/6 inhibition is a promising approach for the treatment of bladder cancer, however, mechanisms of resistance are unclear. Therefore, a genome-scale CRISPR-dCas9 GOF screen for the CDK4/6 inhibitor was performed. 1024 sgRNAs were significantly enriched in the screen. Combination of Palbociclib with compounds directed against RTKs, PI3K-Akt, Ras/MAPK and STAT pathways revealed beneficial effects in vitro and in vivo xenografts. In conclusion, identification of resistance mechanisms and...
»